ArticleImmuno-oncology technology2024

Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial.

K S Shohdy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.